Trial Profile
Function of Inflammation Factors in Aflibercept or Ranibizumab Treatment on Alleviating Wet Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 21 Aug 2018 New trial record